Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments

European Journal of Endocrinology

Volumn 172, Issue 2, 2015, Pages 115-122

  Ramos Leví, Ana M ^a   Marazuela, Monica ^a   Paniagua, Amalia ^b   Quinteiro, Celsa ^c   Riveiro, Javier ^d   Álvarez Escolá, Cristina ^e   Lucas, Tomas ^f   Blanco, Concepcion ^g   De Miguel, Paz ^h   De Icaya, Purificacion Martínez ⁱ   Pavón, Isabel ^j   Bernabeu, Ignacio ^c  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b HOSPITAL UNIVERSITARIO REY JUAN CARLOS   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f Facultad HM Hospitales de Ciencias de la Salud de la UCJC   (Spain)

^g HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL SEVERO OCHOA   (Spain)

^j HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN 3;

ACROMEGALY; ADULT; ALLELE; ARTICLE; CA REPEAT; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL POLYP; DNA POLYMORPHISM; DNA STRUCTURE; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IGF1 GENE; IGFBP3 GENE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ACROMEGALY; ADULT; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922537956     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0613     Document Type: Article

References (33)

1. Katznelson L, Atkinson JL, Cook D.M., Ezzat SZ, Hamrahian AH, Miller KK & AACE Acromegaly Task Force. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of acromegaly 2011 update: executive summary. Endocrine Practice 2011 4 636-646. (doi:10.4158/Ep.17.4.636)
2. Ali O, Cohen P & Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Hormone and Metabolic Research 2003 35 726-733. (doi:10.1055/s-2004-814146)
3. Rosen CJ, Kurland ES, Vereault D, Adler R.A., Rackoff PJ, Craig WY, Witte S, Rogers J & Bilezikian JP. Association between serum insulin growth factor-I (IGF1) and a simple sequence repeat in IGF1 gene: implications for genetic studies of bone mineral density. Journal of Clinical Endocrinology and Metabolism 1998 83 2286-2290. (doi:10.1210/jcem.83.7.4964)
4. Rietveld I, Janssen JA, van Rossum EF, Houwing-Duistermaat JJ, Rivadeneira F, Hofman A., Pols HA, van Duijn CM & Lamberts SW. A polymorphic CA repeat in the IGF1 gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clinical Endocrinology 2004 61 195-203. (doi:10.1111/j.1365-2265.2004.02078.x)
5. Vaessen N, Heutink P, Janssen J.A., Witteman JC, Testers L, Hofman A, Lamberts S.W., Oostra BA, Pols HA & van Duijn CM. A polymorphism in the gene for IGF1: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001 50 637-642. (doi:10.2337/diabetes.50.3.637)
6. Vaessen N, Janssen JA, Heutink P, Hofman A., Lamberts SW, Oostra BA, Pols HA & van Duijn CM. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 2002 359 1036-1037. (doi:10.1016/S0140-6736(02)08067-4)
7. Rietveld I, Janssen JA, Hofman A, Pols H.A., van Duijn CM & Lamberts SW. A polymorphism in the IGF1 gene influences the age-related decline in circulating total IGF1 levels. European Journal of Endocrinology 2003 148 171-175. (doi:10.1530/eje.0.1480171)
8. Allen NE, Davey GK, Key T.J., Zhang S & Narod SA. Serum insulin-like growth factor I (IGF1) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF1 gene. Cancer Epidemiology, Biomarkers & Prevention 2002 11 319-320.
9. Miletta MC, Scheidegger UA, Giordano M, Bozzola M., Pagani S, Bona G, Dattani M., Hindmarsh PC, Petkovic V, Oser-Meier M et al. Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency. Clinical Endocrinology 2012 76 683-690. (doi:10.1111/j.1365-2265.2011.04267.x)
10. Frayling TM, Hattersley AT, McCarthy A, Holly J., Mitchell SM, Gloyn AL, Owen K, Davies D., Smith GD & Ben-Shlomo Y. A putative functional polymorphism in the IGF1 gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 2002 51 2313-2316. (doi:10.2337/diabetes.51.7.2313)
11. Rasmussen SK, Lautier C, Hansen L., Echwald SM, Hansen T, Ekstrøm CT, Urhammer S.A., Borch-Johnsen K, Grigorescu F, Smith RJ et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2000 85 1606-1610. (doi:10.1210/jcem.85.4.6494)
12. Yazdanpanah M, Sayed-Tabatabaei FA, Janssen J.A., Rietveld I., Hofman A, Stijnen T, Pols H.A., Lamberts SW, Witteman JC & van Duijn CM. IGF1 gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. European Journal of Endocrinology 2006 155 751-756. (doi:10.1530/eje.1.02276)
13. Costalonga EF, Antonini SR, Guerra G Jr, Coletta RR, Franca MM, Braz AF, Mendonca B.B., Arnhold IJ & Jorge AA. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. Pharmacogenomics Journal 2012 12 439-445. (doi:10.1038/tpj.2011.13)
14. Costalonga EF, Antonini SR, Guerra G Jr, Mendonca BB, Arnhold IJ & Jorge AA. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2009 94 588-595. (doi:10.1210/jc.2008-1608)
15. Braz AF, Costalonga EF, Montenegro L.R., Trarbach EB, Antonini SR, Malaquias AC, Ramos E.S., Mendonca BB, Arnhold IJ & Jorge AA. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2012 97 E671-E677. (doi:10.1210/jc.2011-2521)
16. Quan H, Tang H, Fang L., Bi J, Liu Y & Li H. IGF1(CA)19 and IGFBP-3-202A/C gene polymorphism and cancer risk: a meta-analysis. Cell Biochemistry and Biophysics 2014 69 169-178. (doi:10.1007/s12013-013-9784-4)
17. Deal C, Ma J, Wilkin F., Paquette J, Rozen F, Ge B., Hudson T, Stampfer M & Pollak M. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. Journal of Clinical Endocrinology and Metabolism 2001 86 1274-1280. (doi:10.1210/jcem.86.3.7280)
18. Al-Zahrani A., Sandhu MS, Luben R.N., Thompson D., Baynes C, Pooley KA, Luccarini C, Munday H., Perkins B, Smith P et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Human Molecular Genetics 2006 15 1-10. (doi:10.1093/hmg/ddi398)
19. Hendriks AE, Brown MR, Boot A.M., Oostra BA, de Jong FH, Drop SL & Parks JS. Common polymorphisms in the GH/IGF-1 axis contribute to growth in extremely tall subjects. Growth Hormone & IGF Research 2011 21 318-324. (doi:10.1016/j.ghir.2011.08.001)
20. van der Kaay DC, Hendriks AE, Ester W.A., Leunissen RW, Willemsen RH, de Kort SW, Paquette JR, Hokken-Koelega AC & Deal CL. Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age. Growth Hormone & IGF Research 2009 19 198-205. (doi:10.1016/j.ghir.2008.08.010)
21. Bernabeu I, Alvarez-Escola C, Quinteiro C., Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 222-229. (doi:10.1210/jc.2009-1630)
22. Marazuela M, Paniagua AE, Gahete M.F., Lucas T., Alvarez-Escola C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. Journal of Clinical Endocrinology and Metabolism 2011 96 E251-E259. (doi:10.1210/jc.2010-1742)
23. Melmed S, Casanueva FF, Klibanski A, Bronstein M.D., Chanson P., Lamberts SW, Strasburger CJ, Wass JAH & Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013 16 294-302. (doi:10.1007/s11102-012-0420-x)
24. Akin F, Turgut S, Cirak B & Kursunluogly R. IGF(CA)19 and IGFBP3-202A/C gene polymorphism in patients with acromegaly. Growth Hormone & IGF Research 2010 20 399-403. (doi:10.1016/j.ghir.2010.09.001)
25. Giavoli C, Profka E, Sala E., Filopanti M, Barbieri AM, Bergamaschi S, Ferrante E., Arosio M, Ambrosi B, Lania AG et al. Impact of IGF(CA)19 gene polymorphism on the metabolic response to GH therapy in adult GH-deficient patients. European Journal of Endocrinology 2014 170 273-281. (doi:10.1530/EJE-13-0600)
26. Naylor LH & Clark EM. d(TG)n: d(CA)n sequences upstream of the rat prolactin gene from Z-DNA and inhibit gene transcription. Nucleic Acids Research 1990 18 1595-1600. (doi:10.1093/nar/18.6.1595)
27. Misra M, Cord J, Prabhakaran R., Miller KK & Klibanski A. Growth hormone suppression after an oral glucose load in children. Journal of Clinical Endocrinology and Metabolism 2007 92 4623-4629. (doi:10.1210/jc.2007-1244)
28. Schernhammer ES, Hankinson SE, Hunter D.J., Blouin MJ & Pollak MN. Polymorphic variation at the 202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. International Journal of Cancer 2003 107 60-64. (doi:10.1002/ijc.11358)
29. Morimoto LM, Newcomb PA, White E, Bigler J & Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiology, Biomarkers & Prevention 2005 14 1394-1401. (doi:10.1158/1055-9965.EPI-04-0694)
30. Soubry A, Il'yasova D, Sedjo R, Wang F, Byers T, Rosen C, Yashin A, Ukraintseva S, Haffner S & D'Angostino R. Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. International Journal of Cancer 2012 131 512-517. (doi:10.1002/ijc.26393)
31. Wernli KJ, Newcomb PA, Wang Y, Makar J.W., Shadman M., Chia VM, Burnett-Hartman A, Wurscher M, Zheng Y & Mandelson MT. Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps. Growth Hormone & IGF Research 2010 20 305-309. (doi:10.1016/j.ghir.2010.04.001)
32. Filopanti M, Ronchi C, Ballarè E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4824-4828. (doi:10.1210/jc.2005-0132)
33. Mercado M, González B, Sandoval C., Esquenazi Y, Mier F, Vargas G., de los Monteros AL & Sosa E. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 3411-3415. (doi:10.1210/jc.2008-0391)